Move to topTop
April 12, 2021

LEUVEN, BELGIUM - April 12, 2021 - Terumo is proud to announce the launch of its Global Therapeutic Interventional Oncology team as of April 1st, 2021. This reflects Terumo's aspiration to be a Global leader in the field of Interventional Oncology by focusing on improving patient's quality of life and survival.

This organization will be comprised of Medical Strategy, Research & Development, Software Development, Medical Imaging Discovery, and Operations. It will be entirely dedicated to the development of Therapeutic Interventional Oncology solutions for patients with cancer. This team will be led by Laurent Domas, Vice President, Global Interventional Oncology Strategy and Therapy Development.

"With this team of specialists, we want to provide excellence in developing Interventional Oncology solutions to improve the clinical benefit for patients with cancer, and thus contribute to society through healthcare ", said Laurent Domas.

Terumo Interventional Systems is a leader in access technologies used in Interventional Oncology procedures and already offers a broad range of therapeutic solutions in EMEA. The Therapeutic Interventional Oncology portfolio comprises drug eluting microspheres with LifePearlTM microspheres, Selective Internal Radiation Therapy solutions with the Holmium platform (QuiremSpheresTM microspheres, QuiremScoutTM microspheres, QSuiteTM software) and Thermal Microwave ablation with TATO*.

The need for minimally invasive cancer treatments is growing to address the continuous rise of cancer in a global aging population. Terumo aims at being a major player in Interventional Oncology by facilitating access to loco-regional treatments for patients with cancer by focusing on innovation and clinical evidence and partnering with Health Care Professionals.

"It is excellent news to see, within Terumo, the launch of a Therapeutic Interventional Oncology focused team, which is a dedicated entity that will help moving fast forward in the booming and promising field of interventional oncology.", said Professor Thierry De Baère, head of Therapeutic Imaging department, Gustave Roussy Institute, Villejuif, France

With this organization in place, Terumo Interventional Systems will accelerate the commercial deployment of the Holmium platform (QuiremSpheresTM microspheres, QuiremScoutTM microspheres, QSuiteTM software) in EMEA. It will further extend the availability of the Holmium platform in other regions, in particular US as the largest radioembolization market but also China and other countries around the globe.

The creation of the Global Therapeutic Interventional Oncology organization will contribute to complete Terumo Interventional Systems' portfolio of solutions for the treatment of cancers in the liver and in other organs. In particular, it currently investigates the development of radiation oncology technologies for the treatment of pancreatic tumors. It will also innovate in new targeted drug delivery solutions.

  • *

    LifePearlTM microspheres is CE marked and available in Europe and is used in the treatment of unresectable primary and secondary liver cancer. It is also available in Russia, Kazakhstan, Saudi Arabia, Latin America, Taiwan and Vietnam. It is not approved in US FDA.

  • QuiremSpheresTM microspheres, QuiremScoutTM microspheres, QSuiteTM software are CE marked and available in Europe for the treatment of unresectable cancers in the liver. It is not approved by US FDA.

  • TATO is CE marked and available in Europe. It is not approved by US FDA.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.